Literature DB >> 19932689

Acute myelogenous leukemia cells with the MLL-ELL translocation convert morphologically and functionally into adherent myofibroblasts.

Haruko Tashiro1, Mitsuho Mizutani-Noguchi, Ryosuke Shirasaki, Naoki Shirafuji.   

Abstract

Bone marrow-myofibroblasts, a major component of bone marrow-stroma, are reported to originate from hematopoietic stem cells. We show in this paper that non-adherent leukemia blasts can change into myofibroblasts. When myeloblasts from two cases of acute myelogenous leukemia with a fusion product comprising mixed lineage leukemia and RNA polymerase II elongation factor, were cultured long term, their morphology changed to that of myofibroblasts with similar molecular characteristics to the parental myeloblasts. The original leukemia blasts, when cultured on the leukemia blast-derived myofibroblasts, grew extensively. Leukemia blasts can create their own microenvironment for proliferation. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19932689     DOI: 10.1016/j.bbrc.2009.11.104

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Vascular endothelial growth factor-C and its receptor type-3 expressed in acute lymphocytic leukemia cases with t(1;19).

Authors:  Ryosuke Shirasaki; Haruko Tashiro; Yoko Oka; Toshihiko Sugao; Tadashi Yamamoto; Mayumi Yoshimi; Nobu Akiyama; Kazuo Kawasugi; Naoki Shirafuji
Journal:  Int J Hematol       Date:  2011-07-06       Impact factor: 2.490

Review 2.  Cancer associated fibroblasts in hematological malignancies.

Authors:  Lizzia Raffaghello; Angelo Vacca; Vito Pistoia; Domenico Ribatti
Journal:  Oncotarget       Date:  2015-02-20

3.  Chronic Myelogenous Leukemia Cells Contribute to the Stromal Myofibroblasts in Leukemic NOD/SCID Mouse In Vivo.

Authors:  Ryosuke Shirasaki; Haruko Tashiro; Yoko Oka; Takuji Matsuo; Tadashi Yamamoto; Toshihiko Sugao; Nobu Akiyama; Kazuo Kawasugi; Naoki Shirafuji
Journal:  J Oncol       Date:  2012-07-15       Impact factor: 4.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.